Immunopharmacology and Immunotoxicology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Tumor cells inhibit the activation of ILC2s through up-regulating PD-1 expression
Immunopharmacol Immunotoxicol. 2024 Apr 28:1-10. doi: 10.1080/08923973.2024.2347315. Online ahead of print.ABSTRACTUp-regulating programmed cell death ligand-1(PD-L1) expressed on tumor cells and tumor-infiltrating myeloid cells interacting with up-regulated programmed cell death-1 (PD-1) expressed on tumor-infiltrating lymphoid cells greatly hinder their tumor-inhibiting effect. It is necessary to explore the deep mechanism of this negative effect, so as to find the potential methods to improve the immunotherapy efficiency. Here, we found that the PD-1 expression in lung cancer-infiltrating type II innate lymphoid cells (...
Source: Immunopharmacology and Immunotoxicology - April 28, 2024 Category: Allergy & Immunology Authors: Chaoyun Yin Yani Pa Guangyu Li Qiang Chen Xizu Wang Xijun He Huangao Zhou Source Type: research

Immunopathogenesis of multiple sclerosis: molecular and cellular mechanisms and new immunotherapeutic approaches
Conclusion: MS remains incurable, but disease-modifying therapies, monoclonal antibodies, and immunomodulatory drugs offer hope for patients. Research on the immunogenetics and immunoregulatory functions of gut microbiota is continuing to provide light on possible treatment avenues. Understanding the complex interplay between genetic predisposition, environmental factors, and immune dysregulation is critical for developing effective treatments for MS.PMID:38634438 | DOI:10.1080/08923973.2024.2330642 (Source: Immunopharmacology and Immunotoxicology)
Source: Immunopharmacology and Immunotoxicology - April 18, 2024 Category: Allergy & Immunology Authors: Mansur Aliyu Fatema Tuz Zohora Ayca Ceylan Fariha Hossain Reza Yazdani Gholamreza Azizi Source Type: research

Immunopathogenesis of multiple sclerosis: molecular and cellular mechanisms and new immunotherapeutic approaches
Conclusion: MS remains incurable, but disease-modifying therapies, monoclonal antibodies, and immunomodulatory drugs offer hope for patients. Ongoing research into the immunogenetics and immunoregulatory roles of gut microbiota continues to shed light on potential therapeutic avenues. Understanding the complex interplay between genetic predisposition, environmental factors, and immune dysregulation is critical for developing effective treatments for MS.PMID:38634438 | DOI:10.1080/08923973.2024.2330642 (Source: Immunopharmacology and Immunotoxicology)
Source: Immunopharmacology and Immunotoxicology - April 18, 2024 Category: Allergy & Immunology Authors: Mansur Aliyu Fatema Tuz Zohora Ayca Ceylan Fariha Hossain Reza Yazdani Gholamreza Azizi Source Type: research

Systematic Review of the Efficacy and Safety of Lenvatinib in Various Solid Tumors
Conclusions Lenvatinib in various solid tumors can prolong OS and disease PFS of patients, improve the clinical benefit rate and improve the quality of life of patients. At the same time, there is a certain incidence of adverse events, and symptomatic intervention should be given in clinical medication.PMID:38627024 | DOI:10.1080/08923973.2024.2344153 (Source: Immunopharmacology and Immunotoxicology)
Source: Immunopharmacology and Immunotoxicology - April 16, 2024 Category: Allergy & Immunology Authors: Shuai Geng Tong Liu Nan Wang Xinyue Gao Xinyu Luo Ning Shi Shuai Jiang Source Type: research

CCL2 regulated by the CTBP1-AS2/miR-335-5p axis promotes hemangioma progression and angiogenesis
Conclusion: Our findings suggest that targeting the CTBP1-AS2/miR-335-5p/CCL2 axis may hold promise as a therapeutic strategy for HA.PMID:38622049 | DOI:10.1080/08923973.2024.2330651 (Source: Immunopharmacology and Immunotoxicology)
Source: Immunopharmacology and Immunotoxicology - April 15, 2024 Category: Allergy & Immunology Authors: Ruixuan Li Ying Liu Jianfeng Liu Bo Chen Zhongjie Ji Aixia Xu Tianhua Zhang Source Type: research

Immunosuppressants against acute kidney injury: what to prefer or to avoid?
Conclusion: Understanding the effects of immunosuppressants on AKI is crucial for optimizing patient care. This review highlights the need for further research to determine the most suitable immunosuppressants for AKI patients, considering both their efficacy and potential side effects.PMID:38477877 | DOI:10.1080/08923973.2024.2330641 (Source: Immunopharmacology and Immunotoxicology)
Source: Immunopharmacology and Immunotoxicology - March 13, 2024 Category: Allergy & Immunology Authors: Swati Mishra Vishwadeep Shelke Neha Dagar Maciej Lech Anil Bhanudas Gaikwad Source Type: research